Soluble epoxide hydrolase in atherosclerosis

Current Atherosclerosis Reports

Volumn 12, Issue 3, 2010, Pages 174-183

  Wang, Yi Xin Jim ^a   Ulu, Arzu ^b   Zhang, Le Ning ^c   Hammock, Bruce ^b  

^a Arete Therapeutics Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MuriGenics Inc   (United States)

Author keywords

Abdominal aortic aneurysm; Angiotensin II; Apolipoprotein E deficient mice; Atherosclerosis; Cytochrome P450; DHET; Dihydroxyeicosatrienoic acid; EET; Eicosanoids; Ephx2 gene polymorphisms; Epoxyeicosatrienoic acid; SEH; Soluble epoxide hydrolase

Indexed keywords

1 (1 METHANESULFONYLPIPERIDIN 4 YL) 3 (4 TRIFLUOROMETHOXYPHENYL)UREA; 1 (1 NICOTINOYLPIPERIDIN 4 YL) 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 ADAMANTAN 3 [5 [2 (2 ETHYLETHOXY)ETHOXY]PENTYL]UREA; APOLIPOPROTEIN E; AR 9276; ENDOTHELIN; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PROSTAGLANDIN SYNTHASE; SOLUBLE EPOXIDE HYDROLASE; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DISEASE COURSE; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME STABILITY; FATTY ACID BLOOD LEVEL; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; HEART INFARCTION SIZE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYDRATION; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROMOTER REGION; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BLOOD; ENZYMOLOGY; GENE THERAPY; GENETIC POLYMORPHISM; GENETICS; PROCEDURES; PROGNOSIS;

ANIMALS; ATHEROSCLEROSIS; EPOXIDE HYDROLASES; GENE THERAPY; HUMANS; POLYMORPHISM, GENETIC; PROGNOSIS; GENETIC THERAPY;

EID: 77953538299     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0108-5     Document Type: Review

References (70)

1. Nissen SE, Nicholls SJ, Sipahi I, et al.: Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
2. Wang M, Song WL, Cheng Y, Fitzgerald GA: Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease. J Intern Med 2008, 263:500-505.
3. Zhang LN, Vincelette J, Cheng Y, et al.: Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol 2009, 29:1265-1270. This article investigated the antiinflammatory mechanisms involved in the anti-atherosclerotic effects of sEH inhibitors.
4. Ulu A, Davis BB, Tsai HJ, et al.: Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol 2008, 52:314-323. This is the first article to demonstrate the antiatherosclerotic effects of sEH inhibitors and correlation of these effects with plasma epoxide to diol levels.
5. Li PL, Campbell WB: Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 1997, 80:877-884.
6. Fleming I: Cytochrome P450 epoxygenases as EDHF synthase (s). Pharmacol Res 2004, 49:525-533.
7. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD: An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005, 46:975-981.
8. Fleming I: Cytochrome p450 and vascular homeostasis. Circ Res 2001, 89:753-762.
9. Morisseau C, Goodrow MH, Dowdy D, et al.: Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci U S A 1999, 96:8849-8854.
10. Node K, Huo Y, Ruan X, et al.: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
11. Morisseau C, Hammock BD: Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 2005, 45:311-333.
12. Schmelzer KR, Kubala L, Newman JW, et al.: Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 2005, 102:9772-9777.
13. Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD: The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 2007, 50:225-237.
14. Yu Z, Xu F, Huse LM, et al.: Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000, 87:992-998.
15. Jung O, Brandes RP, Kim IH, Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005, 45:759-765.
16. Ai D, Pang W, Li N, et al.: Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A 2009, 106:564-569.
17. Inceoglu B, Jinks SL, Schmelzer KR, et al.: Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci 2006, 79:2311-2319.
18. Zhang W, Koerner IP, Noppens R, et al.: Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 2007, 27:1931-1940.
19. Ohtoshi K, Kaneto H, Node K, et al.: Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem Biophys Res Commun 2005, 331:347-350.
20. Inceoglu B, Jinks SL, Ulu A, et al.: Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A 2008, 105:18901-18906.
21. Ai D, Fu Y, Guo D, et al.: Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 2007, 104:9018-9023.
22. Xu D, Li N, He Y, et al.: Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 2006, 103:18733-18738.
23. Li N, Liu JY, Timofeyev V, et al.: Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches. J Mol Cell Cardiol 2009, 47:835-845.
24. Olearczyk JJ, Quigley JE, Mitchell BC, et al.: Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond) 2009, 116:61-70.
25. Dorrance AM, Rupp N, Pollock DM, et al.: An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in strokeprone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2005, 46:842-848.
26. Fornage M, Hinojos CA, Nurowska BW, et al.: Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 2002, 40:485-490.
27. Spiecker M, Darius H, Hankeln T, et al.: Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004, 110:2132-2136.
28. Wei Q, Doris PA, Pollizotto MV, et al.: Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 2007, 190:26-34.
29. Maresh JG, Xu H, Jiang N, et al.: Tobacco smoke dysregulates endothelial vasoregulatory transcripts in vivo. Physiol Genomics 2005, 21:308-313.
30. Lee CR, North KE, Bray MS, et al.: Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006, 15:1640-1649.
31. Sato K, Emi M, Ezura Y, et al.: Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet 2004, 49:29-34.
32. Corenblum MJ, Wise VE, Georgi K, et al.: Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension 2008, 51:567-573.
33. Dreisbach AW, Japa S, Sigel A, et al.: The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens 2005, 18:1276-1281.
34. Fornage M, Boerwinkle E, Doris PA, et al.: Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 2004, 109:335-339.
35. Fornage M, Lee CR, Doris PA, et al.: The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 2005, 14:2829-2837.
36. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, et al.: Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 2003, 64:482-490.
37. Wang YX, Cassis LA: Angiotensin II-induced aortic aneurysms. In A Handbook of Mouse Models for Cardiovascular Diseases. Edited by Xu Q. Chichester, England: Life and Medical Sciences, John Wiley & Sons; 2006:125-136.
38. Zhang LN, da Cunha V, Martin-McNulty B, et al.: Monocyte chemoattractant protein-1 or macrophage inflammatory protein-1alpha deficiency does not affect angiotensin IIinduced intimal hyperplasia in carotid artery ligation model. Cardiovasc Pathol 2007, 16:231-236.
39. Zhang LN, Parkinson JF, Haskell C, Wang YX: Mechanisms of intimal hyperplasia learned from a murine carotid artery ligation model. Curr Vasc Pharmacol 2008, 6:37-43. This review article discussed a mouse model of carotid artery ligation-induced vascular remodeling used in the cited study.
40. Zhang LN, Velichko S, Vincelette J, et al.: Interferon-beta attenuates angiotensin II-accelerated atherosclerosis and vascular remodeling in apolipoprotein E deficient mice. Atherosclerosis 2008, 197:204-211.
41. Zhang LN, Wilson DW, da Cunha V, et al.: Endothelial NO synthase deficiency promotes smooth muscle progenitor cells in association with upregulation of stromal cell-derived factor- 1alpha in a mouse model of carotid artery ligation. Arterioscler Thromb Vasc Biol 2006, 26:765-772.
42. Teramoto T, Sasaki J, Ueshima H, et al.: Goals of dyslipidemia management. J Atheroscler Thromb 2007, 14:209-212.
43. Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000, 35:1-10.
44. EnayetAllah AE, Luria A, Luo B, et al.: Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase. J Biol Chem 2008, 283:36592-36598.
45. Golledge J, Muller J, Daugherty A, Norman P: Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006, 26:2605-2613.
46. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
47. Ross R: Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138(5 Pt 2):S419-S420.
48. Daugherty A, Cassis LA: Mechanisms of abdominal aortic aneurysm formation. Curr Atheroscler Rep 2002, 4:222-227.
49. Martin-McNulty B, Tham DM, da Cunha V, et al.: 17 Betaestradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003, 23:1627-1632.
50. Tham DM, Martin-McNulty B, Wang YX, et al.: Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002, 11:21-30.
51. Wang YX, Martin-McNulty B, Freay AD, et al.: Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice. Am J Pathol 2001, 159:1455-1464.
52. Nobuhiko A, Suganuma E, Babaev VR, et al.: Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:2143-2148.
53. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
54. Fang X, Kaduce TL, Weintraub NL, et al.: Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 2001, 276:14867-14874.
55. Fang X, Weintraub NL, Oltman CL, et al.: Human coronary endothelial cells convert 14,15-EET to a biologically active chain-shortened epoxide. Am J Physiol Heart Circ Physiol 2002, 283:H2306-2314.
56. Galkina E, Ley K: Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:2292-2301.
57. Sun J, Sui X, Bradbury JA, et al.: Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenasederived eicosanoids. Circ Res 2002, 90:1020-1027.
58. Davis BB, Thompson DA, Howard LL, et al.: Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A 2002, 99:2222-2227.
59. Davis BB, Morisseau C, Newman JW, et al.: Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3- dodecyl urea is independent of soluble epoxide hydrolase inhibition. J Pharmacol Exp Ther 2006, 316:815-821.
60. Simpkins AN, Rudic RD, Schreihofer DA, et al.: Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 2009, 174:2086-2095.
61. Kullmann S, Binner P, Rackebrandt K, et al.: Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention. BMC Cardiovasc Disord 2009, 9:48.
62. Imig JD, Hammock BD: Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009, 8:794-805. This is the most recent review article on sEH as a novel therapeutic target for cardiovascular disease.
63. Birnbaum Y, Ye Y, Lin Y, et al.: Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 2006, 114:929-935.
64. Levy BD: Myocardial 15-epi-lipoxin A4 generation provides a new mechanism for the immunomodulatory effects of statins and thiazolidinediones. Circulation 2006, 114:873-875.
65. Planaguma A, Pfeffer MA, Rubin G, et al.: Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A(4). Mucosal Immunol 2010 (in press).
66. Liu JY, Yang J, Inceoglu B, et al.: Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 2010, 79:880-887.
67. De Taeye BM, Morisseau C, Coyle J, et al.: Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity (Silver Spring) 2010, 18:489-498.
68. Cheranov SY, Karpurapu M, Wang D, et al.: An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood 2008, 111:5581-5591.
69. Strumberg D: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005, 41:773-784.
70. Shen HC, Ding F-X, Wang S, et al.: Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement. J Med Chem 2009, 52:5009-5012.